Free Trial
NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

Brainstorm Cell Therapeutics logo
$1.14 -0.03 (-2.56%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$1.15 +0.01 (+1.23%)
As of 07/3/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)

Key Stats

Today's Range
$1.14
$1.19
50-Day Range
$1.06
$1.36
52-Week Range
$0.72
$6.45
Volume
98,008 shs
Average Volume
389,647 shs
Market Capitalization
$11.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
Consensus Rating
Buy

Company Overview

Brainstorm Cell Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

BCLI MarketRank™: 

Brainstorm Cell Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 181st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($3.01) to ($1.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Brainstorm Cell Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Brainstorm Cell Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Brainstorm Cell Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.51% of the float of Brainstorm Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Brainstorm Cell Therapeutics has recently decreased by 13.71%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Brainstorm Cell Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Brainstorm Cell Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.51% of the float of Brainstorm Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Brainstorm Cell Therapeutics has recently decreased by 13.71%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    4 people have added Brainstorm Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.15% of the stock of Brainstorm Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.

  • Read more about Brainstorm Cell Therapeutics' insider trading history.
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCLI Stock News Headlines

Brainstorm Cell Therapeutics Inc. (BCLI) - Yahoo Finance
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

BCLI Stock Analysis - Frequently Asked Questions

Brainstorm Cell Therapeutics' stock was trading at $2.27 at the beginning of 2025. Since then, BCLI shares have decreased by 49.8% and is now trading at $1.14.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) announced its earnings results on Thursday, May, 15th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.07.
Read the conference call transcript
.

Shares of Brainstorm Cell Therapeutics reverse split on the morning of Tuesday, October 1st 2024.The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include CocaCola (KO), Organovo (ONVO), Cardium Therapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Protalix BioTherapeutics (PLX) and Isoray (ISR).

Company Calendar

Last Earnings
5/15/2025
Today
7/06/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCLI
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.00
High Stock Price Target
$30.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+2,531.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.62 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($1.36) per share
Price / Book
-0.84

Miscellaneous

Free Float
8,742,000
Market Cap
$11.22 million
Optionable
Optionable
Beta
0.22

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:BCLI) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners